Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

• Príomhchruthaitheoirí: Lucia Gozzo (Údar), Calogero Vetro (Údar), Serena Brancati (Údar), Laura Longo (Údar), Daniela Cristina Vitale (Údar), Giovanni Luca Romano (Údar), Elisa Mauro (Údar), Paolo Fabio Fiumara (Údar), Cinzia Maugeri (Údar), Marina Silvia Parisi (Údar), Ilaria Dulcamare (Údar), Bruno Garibaldi (Údar), Andrea Duminuco (Údar), Giuseppe Alberto Palumbo (Údar), Francesco Di Raimondo (Údar), Filippo Drago (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently in Europe, too. However, the drug has been used fo...